In a report released yesterday, Tyler Van Buren from TD Cowen maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price target of $35.00.
Tyler Van Buren’s Buy rating for Biohaven Ltd. is anchored on several factors. Notably, he acknowledges the potential of BHV-7000, Biohaven’s product, citing its potential to be the best in its class. This is backed by recent EEG data, which reinforce its clinical profile. Van Buren also expresses confidence in the outcome of the Phase III focal epilepsy study set to begin by year-end.
Van Buren’s optimism extends to the progress of other programs such as TYK2/JAK1, T-alfa, which are on track. He also mentions the MAA validation in the EU as a promising development, even as SCA3 continues to be refined with the FDA. He indicates that data for IgG and OCD could come next year, further boosting the company’s prospects. Overall, these elements contribute to Van Buren’s positive outlook and Buy rating for Biohaven Ltd.
See the top stocks recommended by analysts >>
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BHVN in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Biohaven Ltd. (BHVN) Company Description:
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven’s Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
Read More on BHVN:
- Fly Insider: Biohaven, BJ’s Wholesale Club among weeks’ notable insider trades
- Biohaven reported preclinical data from study of taldefgrobep alfa
- Biotech Alert: Searches spiking for these stocks today
- Biohaven 10.227M share Spot Secondary priced at $22.00
- Biohaven $200M Spot Secondary; price range $22.00-$22.50
